GLP1R and diabetic kidney disease: The following were observed compared with patients who received DPP-4i: (1) those on GLP-1-RA had better protection against long-term diabetes complications (p=0.0054), myocardial infarction (p=0.0452), kidney disease (p=0.0011), and diabetic nephropathy (p=0.0108); and (2) those on SGLT2i had better protection against uncontrolled diabetes (p=0.0236), stroke (p=0.0301), kidney disease (p=0.0000), and diabetic nephropathy (p=0.0023).